Clovis Oncology’s Rubraca granted FDA priority review for advanced prostate cancer
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the U.S. Food and Drug Administration (FDA) has accepted the companys supplemental New Drug Application (sNDA) for Rubraca ... Read More
Wednesday January 15, 2020 0 comments
Clovis updates data on Rubraca clinical trial
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, reinforcing the... Read More
Monday September 30, 2019 0 comments
Clovis Oncology to receive $175M to fund company’s largest clinical trial
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG... Read More
Thursday May 2, 2019 0 comments
Clovis Oncology announces interim results for drug treating pancreatic cancer
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced interim results from an investigator-initiated Phase 2 trial of Rubraca (rucaparib) in platinum-sensitive patients with advanced... Read More
Tuesday April 2, 2019 0 comments
Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy
BOULDER MUNICH -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced Rubraca (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with... Read More
Tuesday March 5, 2019 0 comments
Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the European Commission (EC) has approved the use of Rubraca(rucaparib) for treatment of ovarian cancer. Specifically, the... Read More
Monday January 28, 2019 0 comments
Clovis Oncology announces positive hearing for Rubraca in Europe
BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More
Wednesday December 5, 2018 0 comments
Clovis Oncology receives Breakthrough Therapy designation for Rubraca
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced theU.S. Food and Drug Administration(FDA) has granted Breakthrough Therapy designation for Rubraca (rucaparib) as a monotherapy... Read More
Tuesday October 2, 2018 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
